Cervical cancer screening outcomes in Zambia, 2010-19: a cohort study.

Izukanji Sikazwe , Albert Manasyan , Albert Manasyan , Mulindi Mwanahamuntu
The Lancet Global Health 9 ( 6)

1
2021
Drug repositioning beyond the low-hanging fruits

Miquel Duran-Frigola , Lidia Mateo , Patrick Aloy
Current Opinion in Systems Biology 3 95 -102

8
2017
Systems-Wide Prediction of Enzyme Promiscuity Reveals a New Underground Alternative Route for Pyridoxal 5’-Phosphate Production in E. coli

Matthew A. Oberhardt , Raphy Zarecki , Leah Reshef , Fangfang Xia
PLOS Computational Biology 12 ( 1)

14
2016
Bioactivity Profile Similarities to Expand the Repertoire of COVID-19 Drugs.

Miquel Duran-Frigola , Martino Bertoni , Roi Blanco , Víctor Martínez
Journal of Chemical Information and Modeling 60 ( 12) 5730 -5734

1
2020
Dual fluorescence in 9-amino-2,7,12,17-tetraphenylporphycene

Miquel Duran-Frigola , Roger Tejedor-Estrada , David Sánchez-García , Santi Nonell
Physical Chemistry Chemical Physics 13 ( 21) 10326 -10332

21
2011
Systems analysis of intracellular pH vulnerabilities for cancer therapy.

Erez Persi , Miquel Duran-Frigola , Mehdi Damaghi , William R. Roush
Nature Communications 9 ( 1) 2997

255
2018
Antigen-stimulated PBMC transcriptional protective signatures for malaria immunization

Gemma Moncunill , Anja Scholzen , Maximillian Mpina , Augusto Nhabomba
Science Translational Medicine 12 ( 543)

7
2020
A chemo-centric view of human health and disease

Miquel Duran-Frigola , David Rossell , Patrick Aloy
Nature Communications 5 ( 1) 5676 -5676

18
2014
Modifications of microvascular EC surface modulate phototoxicity of a porphycene anti-ICAM-1 immunoconjugate; therapeutic implications.

Elisabet Rosàs , Pablo Santomá , Miquel Duran-Frigola , Bryan Hernandez
Langmuir 29 ( 31) 9734 -9743

6
2013
Charting the molecular links between driver and susceptibility genes in colorectal cancer.

Rodrigo Arroyo , Miquel Duran-Frigola , Clara Berenguer , Montserrat Soler-López
Biochemical and Biophysical Research Communications 445 ( 4) 734 -738

3
2014
Drug sensitivity in cancer cell lines is not tissue-specific.

Samira Jaeger , Miquel Duran-Frigola , Patrick Aloy
Molecular Cancer 14 ( 1) 40 -40

27
2015
Residues Coevolution Guides the Systematic Identification of Alternative Functional Conformations in Proteins

Pedro Sfriso , Miquel Duran-Frigola , Roberto Mosca , Agustí Emperador
Structure 24 ( 1) 116 -126

38
2016
Recycling side-effects into clinical markers for drug repositioning.

Miquel Duran-Frigola , Patrick Aloy
Genome Medicine 4 ( 1) 3 -3

39
2012
Systematic identification of molecular links between core and candidate genes in breast cancer.

Rodrigo Arroyo , Guillermo Suñé , Andreas Zanzoni , Miquel Duran-Frigola
Journal of Molecular Biology 427 ( 6) 1436 -1450

14
2015
Rationalizing Drug Response in Cancer Cell Lines.

Teresa Juan-Blanco , Miquel Duran-Frigola , Patrick Aloy
Journal of Molecular Biology 430 ( 18) 3016 -3027

7
2018
A PanorOmic view of personal cancer genomes.

Lidia Mateo , Oriol Guitart-Pla , Carles Pons , Miquel Duran-Frigola
Nucleic Acids Research 45

6
2017
Encircling the regions of the pharmacogenomic landscape that determine drug response.

Adrià Fernández-Torras , Miquel Duran-Frigola , Patrick Aloy
Genome Medicine 11 ( 1) 17

6
2019
Exploring the OncoGenomic Landscape of cancer

Lidia Mateo , Oriol Guitart-Pla , Miquel Duran-Frigola , Patrick Aloy
Genome Medicine 10 ( 1) 61 -61

5
2018
Structural systems pharmacology: the role of 3D structures in next-generation drug development.

Miquel Duran-Frigola , Roberto Mosca , Patrick Aloy
Chemistry & Biology 20 ( 5) 674 -684

33
2013
Analysis of Chemical and Biological Features Yields Mechanistic Insights into Drug Side Effects

Miquel Duran-Frigola , Patrick Aloy
Chemistry & Biology 20 ( 4) 594 -603

39
2013